Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 TRIAL DEMONSTRATES 49% CONFIRMED ORR IN THE 30MG ONVANSERTIB DOSE ARM VERSUS 30% CONFIRMED ORR IN THE CONTROL ARM IN INTENT-TO-TREAT POPULATION (N=110) 

CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM ONGOING RANDOMIZED PHASE 2 FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL (CRDF-004)

 VETERAN EXECUTIVE WITH OVER 20 YEARS OF ONCOLOGY LEADERSHIP AND CLINICAL EXPERIENCE WITH PROVEN TRACK RECORD OF SUCCESS IN BRINGING DEVELOPMENT CANDIDATES THROUGH LATE-STAGE CLINICAL DEVELOPMENT

CARDIFF ONCOLOGY APPOINTS DR. ROGER SIDHU AS CHIEF MEDICAL OFFICER AND ANNOUNCES TIMING FOR THE NEXT UPDATE FROM THE CRDF-004 TRIAL IN FIRST-LINE RAS-MUTATED MCRC

 RESULTS FROM PHASE 1B CLINICAL TRIAL EVALUATING ONVANSERTIB + PACLITAXEL FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER DEMONSTRATED 40% OBJECTIVE RESPONSE RATE 

CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM INVESTIGATOR-INITIATED TRIAL OF ONVANSERTIB IN COMBINATION WITH PACLITAXEL IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT ASCO 2025

- COMPLETED ENROLLMENT IN RANDOMIZED PHASE 2 CRDF-004 TRIAL EVALUATING ONVANSERTIB + STANDARD OF CARE FOR THE TREATMENT OF FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC) - - EXPANDED INTELLECTUAL PROPERTY PORTFOLIO WITH SECOND PATENT COVERING TREATMENT OF ALL BEV-NAVE PATIENTS, INCLUDING RAS-MUTATED AND RAS WILD-TYPE MCRC, ACROSS ALL LINES OF THERAPY - - CASH AND INVESTMENTS OF $79.9 MILLION AS OF MARCH 31, 2025, PROJECTED RUNWAY INTO Q1 2027 - SAN DIEGO, MAY 08, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE. OUR LEAD PROGRAM FOR ONVANSERTIB HAS REMAINED ON TRACK IN 2025 WITH THE SUCCESSFUL COMPLETION OF ENROLLMENT IN OUR TRIAL IN FIRST-LINE RAS-MUTATED MCRC, UNDERSCORING OUR DEEP COMMITMENT TO SERVING A PATIENT POPULATION THAT HAS SEEN NO THERAPEUTIC ADVANCEMENTS IN DECADES, SAID MARK ERLANDER, CHIEF EXECUTIVE OFFICER OF CARDIFF ONCOLOGY.

CARDIFF ONCOLOGY REPORTS FIRST QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

THE CLAIMS COVER COMBINATION TREATMENT OF ONVANSERTIB + BEV FOR ALL BEV-NAVE PATIENTS INCLUDING RAS-MUTATED AND RAS WILD TYPE MCRC ACROSS ALL LINES OF THERAPY THROUGH 2043 THE CLAIMS COVER COMBINATION TREATMENT OF ONVANSERTIB + BEV FOR ALL BEV-NAVE PATIENTS INCLUDING RAS-MUTATED AND RAS WILD TYPE MCRC ACROSS ALL LINES OF THERAPY THROUGH 2043

CARDIFF ONCOLOGY ANNOUNCES A SECOND PATENT FOR THE TREATMENT OF MCRC FOR BEV-NAVE PATIENTS

SAN DIEGO, APRIL 15, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT ON APRIL 14, 2025, NON-QUALIFIED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 35,040 SHARES OF ITS COMMON STOCK WERE GRANTED TO ONE NEW EMPLOYEE. THE STOCK OPTIONS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE NEW EMPLOYEE BECOMING AN EMPLOYEE OF CARDIFF ONCOLOGY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CARDIFF ONCOLOGY REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

- INITIAL RESULTS FROM RANDOMIZED PHASE 2 CRDF-004 TRIAL IN RAS-MUT MCRC WERE RELEASED IN DECEMBER 2024 - - ADDITIONAL CLINICAL DATA FROM CRDF-004 TRIAL EXPECTED IN 1H 2025 - SAN DIEGO, APRIL 15, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED COMPLETION OF PATIENT ENROLLMENT IN THE ONGOING PHASE 2 CRDF-004 TRIAL EVALUATING ONVANSERTIB IN COMBINATION WITH STANDARD OF CARE (SOC) FOR THE TREATMENT OF FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC). THE SUCCESSFUL COMPLETION OF ENROLLMENT IN OUR FIRST-LINE TRIAL FOR PATIENTS WITH RAS MUTANT MCRC REPRESENTS AN IMPORTANT MILESTONE IN OUR MISSION TO DEVELOP NEW TREATMENTS FOR A POPULATION WHO HAVE NOT SEEN MEANINGFUL TREATMENT ADVANCEMENTS FOR DECADES.

CARDIFF ONCOLOGY ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CRDF-004 TRIAL EVALUATING ONVANSERTIB FOR THE TREATMENT OF FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER

- ROBUST INITIAL EFFICACY SIGNAL WITH ONVANSERTIB + CHEMO/BEV IN ONGOING FIRST-LINE RAS-MUT METASTATIC COLORECTAL CANCER (MCRC) CLINICAL TRIAL (CRDF-004) -

CARDIFF ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, FEB. 24, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PRESENT AT TWO UPCOMING INVESTOR CONFERENCES. DETAILS OF THE PRESENTATIONS CAN BE FOUND BELOW.

CARDIFF ONCOLOGY TO PRESENT AT UPCOMING INVESTOR CONFERENCES

- MANAGEMENT WILL HOLD A CONFERENCE CALL ON THURSDAY, FEBRUARY 27 AT 4:30 P.M. ET/1:30 P.M. PT - - MANAGEMENT WILL HOLD A CONFERENCE CALL ON THURSDAY, FEBRUARY 27 AT 4:30 P.M. ET/1:30 P.M. PT -

Cardiff Oncology, Inc.

CRDF

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cardiff Oncology, Inc.

CRDF.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRDF